keyword
MENU ▼
Read by QxMD icon Read
search

predictive biomarker bevacizumab

keyword
https://www.readbyqxmd.com/read/29673151/tumor-molecular-profiling-for-an-individualized-approach-to-the-treatment-of-hepatocellular-carcinoma-a-patient-case-study
#1
Kristine Posadas, Anita Ankola, Zhaohai Yang, Nelson S Yee
Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality rate remains among the highest. For advanced HCC, sorafenib has been shown to slightly prolong survival, and regorafenib and nivolumab, both recently approved by the United States Food and Drug Administration (FDA), may produce clinical benefits to a limited extent. Systemic chemotherapy has been shown to produce a modest response, but there is no clinically valid biomarker that can be used to predict which patients may benefit...
April 17, 2018: Biomedicines
https://www.readbyqxmd.com/read/29657584/dynamic-biomarkers-of-response-to-antiangiogenic-therapies-in-colorectal-cancer-a-review
#2
REVIEW
Jesus Rodriguez-Pascual, Antonio Cubillo
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body. Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice...
December 2017: Current Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/29594657/a-predictive-value-of-von-willebrand-factor-for-early-response-to-bevacizumab-therapy-in-recurrent-glioma
#3
Andrea Pace, Chiara Mandoj, Anna Antenucci, Veronica Villani, Isabella Sperduti, Beatrice Casini, Mariantonia Carosi, Alessandra Fabi, Antonello Vidiri, Tatiana Koudriavtseva, Laura Conti
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was to investigate the possible predictive value of baseline demographic, clinical and laboratory parameters for early 3-month response to BV therapy in patients with recurrent glioma. Forty-nine patients with recurrent glioma received BV at 10 mg/kg intravenously every 3 weeks alone or in association with chemotherapy were included in this study...
March 28, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29573206/identification-of-transcriptome-signature-for-predicting-clinical-response-to-bevacizumab-in-recurrent-glioblastoma
#4
Seung Won Choi, Hyemi Shin, Jason K Sa, Hee Jin Cho, Harim Koo, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam
Glioblastomas are among the most fatal brain tumors. Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor. We retrospectively reviewed patients with recurrent GBM who received bevacizumab to identify biomarkers for predicting clinical response to bevacizumab. Following defined criteria, the patients were categorized into two clinical response groups, and their genetic and transcriptomic results were compared...
March 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29535825/tumour-vasculature-immaturity-oxidative-damage-and-systemic-inflammation-stratify-survival-of-colorectal-cancer-patients-on-bevacizumab-treatment
#5
Sinead A Noonan, Maria E Morrissey, Petra Martin, Monika Biniecka, Shane Ó'Meachair, Aoife Maguire, Miriam Tosetto, Blathnaid Nolan, John Hyland, Kieran Sheahan, Diarmuid O'Donoghue, Hugh Mulcahy, David Fennelly, Jacintha O'Sullivan
Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated biological processes, specifically angiogenesis, inflammation and oxidative damage, could stratify the survival outcome of this cohort. Levels of angiogenesis, inflammation and oxidative damage markers were assessed in pre-bevacizumab resected tumour and serum samples of mCRC patients by dual immunofluorescence, immunohistochemistry and ELISA...
February 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29467925/plasma-ykl-40-as-a-biomarker-for-bevacizumab-efficacy-in-patients-with-newly-diagnosed-glioblastoma-in-the-phase-3-randomized-avaglio-trial
#6
Mogens K Boisen, Camilla B Holst, Nicola Consalvo, Olivier L Chinot, Julia S Johansen
YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab. Plasma samples were collected from 563 patients in the randomized, phase 3 AVAglio trial who received bevacizumab or placebo plus radiotherapy/temozolomide. Raw plasma YKL-40 concentrations were converted to age-corrected percentiles of normal healthy YKL-40 levels and divided into quartiles (Q). The impact of baseline plasma YKL-40 level on survival was investigated using Cox regression analyses...
January 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29438092/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-nonsquamous-non-small-cell-lung-cancer
#7
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck
LESSONS LEARNED: The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents...
February 7, 2018: Oncologist
https://www.readbyqxmd.com/read/29424297/use-of-immunotherapy-to-treat-metastatic-breast-cancer
#8
Andrea Nicolini, Vivian Barak, Piermario Biava, Paola Ferrari, Giuseppe Rossi, Angelo Carpi
This article reviews the principal attempts of immune-modulation or immune therapy in metastatic breast cancer. It considers their rationale and reports on results from the relevant key clinical trials. Immune-modulatory or immune-stimulating cytokines used alone or combined with conventional therapies is among the principal approaches of immune manipulation in breast cancer. As this issue was recently reviewed by us, the aim of the current article is to discuss our updated and unpublished data on this topic...
February 9, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29410027/pro-metastatic-activity-of-agr2-interrupts-angiogenesis-target-bevacizumab-efficiency-via-direct-interaction-with-vegfa-and-activation-of-nf-%C3%AE%C2%BAb-pathway
#9
Mengqi Jia, Yanxia Guo, Deyu Zhu, Nianzhao Zhang, Lin Li, Jin Jiang, Yiwen Dong, Qingqing Xu, Xiulei Zhang, Meijuan Wang, Haina Yu, Fang Wang, Keli Tian, Jinsan Zhang, Charles Y F Young, Hongxiang Lou, Huiqing Yuan
Anterior gradient 2 (AGR2), an endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI), is associated with cancer development and malignant progression. Here, we show that high level of AGR2 promotes the aggressive phenotype of prostate cancer (PCa) mouse models developed by either patient-derived xenografts or surgical intra-prostate implantation of PCa cells, associated with enrichment of the blood vessel network in tumor tissues. Angiogenesis markers VEGFR2 and CD34, accompanied with the invasive marker Vimentin, were predominantly stained in metastatic liver tissues...
May 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29393706/biomarkers-in-recurrent-grade-iii-glioma-patients-treated-with-bevacizumab-and-irinotecan
#10
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm, Hans Skovgaard Poulsen
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort...
February 2, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29361687/circulating-plasma-levels-of-mir-20b-mir-29b-and-mir-155-as-predictors-of-bevacizumab-efficacy-in-patients-with-metastatic-colorectal-cancer
#11
Paola Ulivi, Matteo Canale, Alessandro Passardi, Giorgia Marisi, Martina Valgiusti, Giovanni Luca Frassineti, Daniele Calistri, Dino Amadori, Emanuela Scarpi
Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa)...
January 20, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29355613/histopathological-growth-patterns-as-a-candidate-biomarker-for-immunomodulatory-therapy
#12
REVIEW
Pieter-Jan van Dam, Sofie Daelemans, Elizabeth Ross, Yannick Waumans, Steven Van Laere, Emily Latacz, Roanne Van Steen, Christel De Pooter, Mark Kockx, Luc Dirix, Peter B Vermeulen
The encroachment of a growing tumor upon the cells and structures of surrounding normal tissue results in a series of histopathological growth patterns (HGPs). These morphological changes can be assessed in hematoxylin-and-eosin (H&E) stained tissue sections from primary and metastatic tumors and have been characterized in a range of tissue types including liver, lung, lymph node and skin. HGPs in different tissues share certain general characteristics like the extent of angiogenesis, but also appropriate tissue-specific mechanisms which ultimately determine differences in the biology of HGP subtypes...
January 26, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29350455/a-novel-prognostic-six-cpg-signature-in-glioblastomas
#13
An-An Yin, Nan Lu, Amandine Etcheverry, Marc Aubry, Jill Barnholtz-Sloan, Lu-Hua Zhang, Jean Mosser, Wei Zhang, Xiang Zhang, Yu-He Liu, Ya-Long He
AIMS: We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize individual treatment of patients with glioblastoma (GBM). METHODS: A six-CpG panel was identified by incorporating genome-wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk-score model. Different validation sets of GBMs and lower-grade gliomas and different statistical methods were implemented for prognostic evaluation...
March 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29333924/dynamic-mr-imaging-for-functional-vascularization-depends-on-tissue-factor-signaling-in-glioblastoma
#14
Xiao Chen, Tian Xie, Jingqin Fang, Wei Xue, Houyi Kang, Haipeng Tong, Yu Guo, Bo Zhang, Sumei Wang, Yizeng Yang, Weiguo Zhang
Glomeruloid vascular proliferation (GVP) is a diagnostic hallmark and links to aggressive behavior, therapy resistance and poor prognosis in glioblastoma (GBM). It lacks clinical approaches to predict and monitor its formation and dynamic change. Yet the mechanism of GVPs also remains largely unknown. Using an in situ GBM xenograft mouse model, combined clinical MRI images of pre-surgery tumor and pathological investigation, we demonstrated that the inhibition of tissue factor (TF) decreased GVPs in Mouse GBM xenograft model...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29305787/molecular-profiling-of-short-term-and-long-term-surviving-patients-identifies-cd34-mrna-level-as-prognostic-for-glioblastoma-survival
#15
Signe Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, Helle Broholm, Ulrik Lassen, Hans Skovgaard Poulsen
Despite extensive treatment, overall survival (OS) for glioblastoma (GBM) remains poor. A small proportion of patients present long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are insufficiently understood. Accordingly, study aim was to identify independent prognostic biomarkers for survival. Study cohort consisted of 93 primary GBM patients treated with radiation-, chemo- and bevacizumab therapy, among which 14 STS (OS ≤ 12 months) and 6 LTS (OS ≥ 36 months) were identified, all confirmed being IDH wild-type...
January 5, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29146617/cure-in-advanced-renal-cell-cancer-is-it-an-achievable-goal
#16
Dhanusha Sabanathan, John J Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney
BACKGROUND: Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%-30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29134647/serial-profiling-of-circulating-tumor-dna-for-optimization-of-anti-vegf-chemotherapy-in-metastatic-colorectal-cancer-patients
#17
Masami Yamauchi, Yuji Urabe, Atsushi Ono, Daiki Miki, Hidenori Ochi, Kazuaki Chayama
Understanding the molecular changes in tumors in response to anti-VEGF chemotherapy is crucial for optimization of the treatment strategy for metastatic colorectal cancer. We prospectively investigated changes in the amount and constitution of circulating tumor DNA (ctDNA) in serial peripheral blood samples during chemotherapy. Sixty-one plasma samples taken at different time points (baseline, remission, and post-progression) and pre-treatment tumor samples were collected from 21 patients who received bevacizumab-containing first-line chemotherapy...
April 1, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29078212/-current-status-of-targeted-treatment-in-breast-cancer
#18
Katharina Seiffert, Barbara Schmalfeldt, Volkmar Müller
Within the last years, significant improvements have been achieved in breast cancer treatment, particularly with the development of targeted therapies. Major progress has been made in identifying the drivers malignant growth in oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of the cyclin-dependent kinases CDK4 and CDK6 like palbociclib and inhibitors of mTOR substantially improve progression-free survival...
November 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29064750/the-attenuation-distribution-across-the-long-axis-of-breast-cancer-liver-metastases-at-ct-a-quantitative-biomarker-for-predicting-overall-survival
#19
Richard G Abramson, Nikita Lakomkin, Allison Hainline, Hakmook Kang, M Shane Hutson, Carlos L Arteaga
OBJECTIVE: The objective of our study was to compare attenuation distribution across the long-axis (ADLA) measurements, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and Choi criteria for predicting overall survival (OS) in patients with metastatic breast cancer treated with bevacizumab. MATERIALS AND METHODS: We obtained HIPAA-compliant data from a prospective, multisite, phase 3 trial of bevacizumab for the treatment of metastatic breast cancer...
January 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29059427/microvascular-density-as-a-predictive-biomarker-for-bevacizumab-survival-benefit-in-ovarian-cancer-back-to-first-principles
#20
Napoleone Ferrara
No abstract text is available yet for this article.
November 1, 2017: Journal of the National Cancer Institute
keyword
keyword
93667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"